Ariana Pelosci

New findings reveal significant PFS benefits of T-DXd plus pertuzumab over traditional therapies for HER2-positive advanced breast cancer patients.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.

Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved patient outcomes.

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating myelofibrosis-related anemia.

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

The ShorTrip trial found that short-course radiotherapy followed by FOLFOX and FOLFOXIRI improved pathological response rates in locally advanced rectal cancer.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Amivantamab plus chemotherapy significantly improved PFS and ORR in EGFR-mutated NSCLC patients resistant to osimertinib, regardless of resistance mechanisms.

Adagrasib plus pembrolizumab improved efficacy in KRAS G12C-mutant NSCLC, according to data from the KRYSTAL-7 trial.

Nivolumab with cisplatin and radiotherapy improved disease-free survival in high-risk locally advanced squamous cell carcinoma of the head and neck in the NIVOPOSTOP trial.

A large study found GLP-1 drugs don't raise cancer risk; instead, they cut obesity-related cancers by 7% and overall mortality by 8%.

A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.

Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers Symposium.

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Cabozantinib plus nivolumab and ipilimumab maintained a progression-free survival benefit at 45 months vs placebo in advanced kidney cancer.

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

Single-cycle neoadjuvant pembrolizumab proved safe and effective in dMMR colon cancer, per RESET-C trial findings.

Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.

Lutetium 177 dotatate showed activity and met the PFS end point in patients with surgery- or radiation-refractory grade 2/3 meningioma, per a phase 2 trial presented at ASTRO 2024.

Cladribine plus venetoclax improved complete response and CR with incomplete count recovery rates in MRD-negative patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.

Non-operative management showed promising results for patients with mismatch repair proficient locally advanced rectal cancer, preserving organs without compromising survival.

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.